Recombinant Mouse IL-28A/IFN-lambda 2 Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IL-28A/IFN-lambda 2 Protein, CF Summary

• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 0.0800-0.800 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse IL-28A/IFN-lambda 2 protein
  Asp20-Val193, with a C-terminal 6-His tag
• Accession #: NP_001019844
• N-terminal Sequence: Asp20
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 20.5 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 25 kDa and 30 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IL-28A/IFN-lambda 2 Protein, CF

• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL-28A (also named interferon-lambda 2, IFN-lambda 2), IL-28B (IFN-lambda 3) and IL-29 (IFN-lambda 1) are type III interferons that are class II cytokine receptor ligands (1 - 4). They are distantly related to members of the IL-10 family and type I IFN family (1 - 4). Mouse IL-28A cDNA encodes a 193 amino acid (aa) protein with a 19 aa signal peptide and a 174 aa mature protein that lacks N-glycosylation sites. Mature mouse IL-28A shares 81% and 66% aa sequence identity with rat and human IL-28A, respectively, and functions across species (5). Mouse IL-28A and IL-28B share 97% aa identity; the mouse lacks a functional IL-29 gene (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2 - 6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor  beta (IL-10 R beta ) and IL-28 receptor  alpha (IL-28 R alpha ; also called IFN-lambda  R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1 - 3). Both type I and III IFNs induce antiviral activity and upregulate MHC class I antigen expression (2 - 6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-gamma in serum, suggesting that the robust antiviral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9 - 11).

1. Chen, Q. et al. (2006) Vitam. Horm. 74:207.
2. Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
4. Bartlett, N.W. et al. (2005) J. Gen. Virol. 86:1589.
5. Ank, N. et al. (2006) J. Virol. 80:4501.
6. Onoguchi, K. et al. (2007) J. Biol. Chem. 282:7576.
7. Siebler, J. et al. (2007) Gastroenterology 132:358.
8. Meager, A. et al. (2005) Cytokine 31:109.
9. Lasfar, A. et al. (2006) Cancer Res. 66:4468.
10. Sato, A. et al. (2006) J. Immunol. 176:7686.
11. Zitzmann, K. et al. (2006) Biochem. Biophys. Res. Commun. 344:1334.

Publications for IL-28A/IFN-lambda 2 (4635-ML/CF)(10)

Publications using 4635-ML/CF

• N Zoellner, N Coesfeld, FH De Vos, J Denter, HC Xu, E Zimmer, B Knebel, H Al-Hasani, S Mossner, PA Lang, DM Floss, J Scheller Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling Frontiers in Microbiology, 2022-09-02;13(0):947169. 2022-09-02 [PMID: 36118237] (Bioassay, Mouse)
• J Won, A Jo, CH Gil, S Kim, H Shin, H Jik Kim Inhaled delivery of recombinant interferon-lambda restores allergic inflammation after development of asthma by controlling Th2- and Th17-cell-mediated immune responses International immunopharmacology, 2022-08-27;112(0):109180. 2022-08-27 [PMID: 36030690] (In Vivo, Mouse)
• G Jhala, B Krishnamur, TC Brodnicki, T Ge, S Akazawa, C Selck, PM Trivedi, EG Pappas, L Mackin, N Principe, E Brémaud, DJ De George, L Boon, I Smyth, J Chee, TWH Kay, HE Thomas Interferons limit autoantigen-specific CD8+ T-cell expansion in the non-obese diabetic mouse Cell Reports, 2022-04-26;39(4):110747. 2022-04-26 [PMID: 35476975] (Cell Culture, Mouse)
• A Fedoriw, L Shi, S O'Brien, KN Smitheman, Y Wang, J Hou, C Sherk, S Rajapurkar, J Laraio, LJ Williams, C Xu, G Han, Q Feng, MT Bedford, L Wang, O Barbash, RG Kruger, P Hwu, HP Mohammad, W Peng Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response Cancer Immunology Research, 2022-04-01;0(0):. 2022-04-01 [PMID: 35181787] (Bioassay, Human)
• J Ardanuy, K Scanlon, C Skerry, SY Fuchs, NH Carbonetti Age-Dependent Effects of Type I and Type III IFNs in the Pathogenesis of Bordetella pertussis Infection and Disease J. Immunol., 2020-03-09;0(0):. 2020-03-09 [PMID: 32152071] (In Vivo, Mouse)
• AT Liou, CC Liao, SF Chou, YS Chang, CS Chang, C Shih Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model J. Biomed. Sci., 2019-11-11;26(1):93. 2019-11-11 [PMID: 31711481] (In Vivo, Mouse)
• TA Nguyen, BRC Smith, KD Elgass, SJ Creed, S Cheung, MD Tate, GT Belz, IP Wicks, SL Masters, KC Pang SIDT1 Localizes to Endolysosomes and Mediates Double-Stranded RNA Transport into the Cytoplasm J. Immunol., 2019-05-06;0(0):. 2019-05-06 [PMID: 31061008] (Cell Culture, Mouse)
• MT Stier, K Goleniewsk, JY Cephus, DC Newcomb, TP Sherrill, KL Boyd, MH Bloodworth, ML Moore, K Chen, JK Kolls, RS Peebles STAT1 Represses Cytokine-Producing Group 2 and Group 3 Innate Lymphoid Cells during Viral Infection J. Immunol., 2017-06-02;0(0):. 2017-06-02 [PMID: 28576981] (Bioassay, Mouse)
• Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A, 2012-06-04;109(25):9971-6. 2012-06-04 [PMID: 22665806] (Bioassay, Mouse)
• Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S, Mori Y, Kunisawa J, Kiyono H, Itoh N, Nagano K, Kamada H, Tsutsumi Y, Tsunoda S Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J. Virol., 2010-09-29;84(24):12703-12. 2010-09-29 [PMID: 20881038] (In Vivo, Mouse)

Bioinformatics

• Uniprot:
  • NP_001019844()